The PD-1/PD-L1 pathway is a major driver of immunosuppression within the tumor microenvironment, and AREG-mediated upregulation of PD-L1 on tumor cells may explain the significantly reduced progression free survival observed in prostate cancer samples with higher levels of stromal senescence (Xu et al., 2019). Here, CD274 is linked to prostate cancer.